Scopece Luciano, Franceschi Enrico, Cavallo Giovanna, Paioli Anna, Paioli Gabriele, Conforti Rosa, Palmerini Emanuela, Berzioli Carlotta, Spagnolli Federica, Esposti Roberta Degli, Crinò Lucio
Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139 Bologna, Italy.
J Neurooncol. 2006 Sep;79(3):299-305. doi: 10.1007/s11060-006-9144-y. Epub 2006 Apr 28.
Oligodendroglial tumors are rare and chemosensitive diseases; but the overall results with current chemotherapy regimens cannot be considered satisfactory and other active treatments are necessary. We decided to determine the efficacy and toxicity profile of the carboplatin and etoposide (CE) regimen in this setting.
In this phase II trial we evaluated the response rate of first or second line CE regimen (Carboplatin AUC 5 on day 1 and Etoposide 120 mg/m2 on days 1-3 every 28 days) in patients with recurrent/progressive oligodendroglial tumors.
Thirty-two patients were enrolled. Median age was 42 years (range 22-66); median ECOG PS was 0 (range 0-2); 9 patients had oligodendroglioma, 3 patients had oligoastrocytoma, 11 patients had anaplastic oligodendroglioma, 9 patients had anaplastic oligoastrocytoma. CE regimen showed a response rate of 46.9% with 5 complete responses (15.6%) and 10 partial responses (31.3%). Eleven patients (34.4%) had stable disease. Median time to progression was 8 months, progression-free survivals at 6 and 12 months were 80% and 46.9%, respectively. Toxicity was mainly hematological, with grade 3-4 neutropenia in 5 (15.6%) patients.
In this trial CE regimen has shown relevant activity with a favourable safety profile.
少突胶质细胞瘤是罕见且对化疗敏感的疾病；但目前化疗方案的总体效果并不令人满意，需要其他有效的治疗方法。我们决定在此情况下确定卡铂和依托泊苷（CE）方案的疗效和毒性特征。
在这项II期试验中，我们评估了复发/进展性少突胶质细胞瘤患者一线或二线CE方案（第1天卡铂AUC 5，第1 - 3天依托泊苷120 mg/m²，每28天一次）的缓解率。
32例患者入组。中位年龄为42岁（范围22 - 66岁）；中位ECOG体能状态为0（范围0 - 2）；9例为少突胶质细胞瘤，3例为少突星形细胞瘤，11例为间变性少突胶质细胞瘤，9例为间变性少突星形细胞瘤。CE方案的缓解率为46.9%，其中5例完全缓解（15.6%），10例部分缓解（31.3%）。11例患者（34.4%）疾病稳定。中位进展时间为8个月，6个月和12个月的无进展生存率分别为80%和46.9%。毒性主要为血液学毒性，5例（15.6%）患者出现3 - 4级中性粒细胞减少。
在本试验中，CE方案显示出显著活性且安全性良好。
